Skip to main content
In stock | Immunotherapy (Investigational)

Obrixtamig

Oncology Type Solid Tumour
Drug Class / Mechanism Bispecific T-Cell Engager, DLL3 x CD3
No Image
Description

Obrixtamig is classified as a Bispecific T-Cell Engager, DLL3 x CD3, sourced for use within our Immunotherapy (Investigational) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Immunotherapy (Investigational)
Oncology Type Solid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3